Quick Facts

• May be recommended for the management of various vulvovaginal infections.
• Used in therapeutic regimens for conditions like trichomoniasis.
• May be utilized to address candidiasis and bacterial vaginosis.

---

Экофуцин (Nifuratel) is a therapeutic option considered for the management of infections of the genito-urinary tract, primarily focusing on vulvovaginal concerns. It is an agent that helps address infections caused by protozoa, fungi, and bacteria. The medication may be included in treatment plans for conditions such as trichomoniasis, a type of protozoal infection.

Clinical experience suggests its utility in treating vulvovaginal candidiasis (fungal infections) and bacterial vaginosis. Due to its spectrum of activity, it is often considered for patients presenting with mixed vaginal infections, where a combination of different organisms may be responsible for symptoms. Healthcare professionals can provide tailored guidance on the appropriate use of this medication in a patient's care plan.

Who can and cannot use Экофуцин?

This section defines the official eligibility and non-eligibility criteria for using Экофуцин (Natamycin) as documented in governmental regulatory sources.

---

Contraindications and Restricted Use

Category	Eligibility Rule
Absolute Contraindication	Use is strictly prohibited in patients with known hypersensitivity to the active substance Natamycin or any of the product's excipients (such as hard fat or lactulose).
Restricted Use	No specific restrictions are officially documented for patients with compromised hepatic or renal function due to the medicine's localized action and minimal systemic absorption.

Special Population Eligibility

Category	Regulatory Status
Pregnancy	Use is permitted throughout all trimesters.
Lactation (Breastfeeding)	Use is permitted during the breastfeeding period.
Age Groups	No specific restrictions are imposed on older adults; pediatric/adolescent use is generally dictated by the indication.

The regulatory profile is structured by a single absolute exclusion: a history of hypersensitivity to the drug's components. The official labeling confirms that its use is allowed for pregnant and breastfeeding women, making these groups eligible under standard labeled conditions. The absence of organ function restrictions is consistent with the drug's localized route of administration.

Interactions with other medicines and products — Official Regulatory Information

The official regulatory profile for Экофуцин, which contains the active substance Nifuratel, documents specific interactions that modify the efficacy of co-administered medicines and impose constraints on substance consumption.

Documented Interaction Scope

Interacting Product Category	Official Description of Interaction Outcome
Coumarin Anticoagulants	Co-administration results in a potentiation of the anticoagulant effect, requiring specific monitoring and management of the anticoagulant substance.
Alcohol	Consumption should be limited or avoided during the course of treatment.

Official Interaction Statements

• The interaction with anticoagulants is classified as a clinically significant pharmacodynamic interaction that functionally increases the therapeutic effect of the anticoagulant (e.g., Warfarin, Acenocoumarol). This effect necessitates patient monitoring of the International Normalized Ratio (INR).
• The regulatory context includes a clear restriction concerning alcohol consumption.
• No substances are formally designated as a contraindicated combination in the official prescribing information.
• No explicit CYP-mediated or transporter-based mechanisms are documented, nor are mandatory timing-based separation rules specified for administration.

Connection to the Overall Interaction Profile

Regulatory documents define the product’s interaction structure primarily through its effect on co-administered coumarin anticoagulants and the restriction on alcohol. The profile is marked by the absence of formally documented complex pharmacokinetic mechanisms or specific population-based interaction cautions, focusing instead on the potential for increased anticoagulant efficacy.

Mechanism of Action: How Экофуцин Works

Экофуцин's active substance, natamycin, is a polyene macrolide that exerts its effect through a highly selective interaction with fungal cell membranes. The drug acts as a strong binder to ergosterol, a sterol molecule that is an essential structural component found exclusively in the plasma membranes of sensitive fungal cells. This specific molecular targeting is the foundational step that ensures the drug's mechanism is engaged by the target pathogen.

The binding of natamycin to ergosterol leads to the formation of pores or channels that compromise the membrane's selective permeability. This disruption results in the leakage of essential intracellular components and prevents nutrient uptake, irreversibly damaging the fungal cell's ability to regulate its internal environment. This structural and functional damage to the fungal cell ultimately leads to both a fungistatic action (arrested growth and reproduction) and a fungicidal action (direct cell death), resulting in a reduction in the local population of the fungal organism.

The usage of Экофуцин, which contains Natamycin, is determined by the specific administration route and form. The medication is used via the intravaginal route in the form of a 100 mg suppository for local conditions, and via oral 100 mg tablets when addressing a focus of infection in the intestine. A topical cream and an ophthalmic suspension also exist, indicating varied administrative principles for the active substance.

For vaginal use, the standard regimen is one 100 mg suppository once daily. This single dose is typically administered at night and should be inserted deeply while the patient is lying down. The treatment course is defined as short-term, typically lasting 3 to 6 days. A key procedural constraint is the requirement to interrupt administration during menstruation to ensure the integrity of the treatment course.

When the oral tablet is used for intestinal concerns, the standard adult regimen is one 100 mg tablet four times a day. The intake of the oral tablets is independent of food. For pediatric patients, the frequency is adjusted to one 100 mg tablet twice a day for the intestinal regimen. These protocols define the standardized, procedural approach to using the medicine, focusing on ensuring the correct dose is delivered via the appropriate route for the defined duration.

Research evidence / Overview of studies for Экофуцин

Evidence for Natamycin in Vulvovaginal Candidiasis

Research was studied for its use in conditions associated with acute or disruptive episodes, specifically Vulvovaginal Candidiasis (VVC). The evidence base includes international randomized controlled trials (RCTs) that examined outcomes related to physical discomfort and systemic or functional imbalance. These trials typically monitored patient groups of non-pregnant adult females. The primary goals of the research were to measure both clinical status (tracking symptoms like burning or itching) and microbiological pathogen status (tracking the presence of Candida fungus identified by lab culture).

Studies have explored the short-term symptom changes measured during the study period and reported patterns observed in relation to the fungal pathogen status. Findings describe patterns observed in these studies when compared to a reference treatment. However, the follow-up durations were limited in many published studies, meaning that long-term effects are not fully established, particularly concerning the recurrence of VVC.

---

Evidence for Nifuratel in Trichomoniasis

Nifuratel was studied for its use in conditions associated with acute or disruptive episodes, specifically Trichomoniasis. Research examined the compound through meta-analyses of controlled clinical trials, which pool data from multiple studies. The primary outcome was observed in these trials was the overall study endpoint, defined by the combined assessment of symptoms and microbiological confirmation of pathogen status.

Research highlights changes measured during the study period, reporting patterns related to the study's defined study endpoint when compared to a reference treatment. The findings describe group patterns where Nifuratel was associated with outcomes observed in studies alongside a reference treatment. Uncertainty remains because the evidence used in meta-analyses sometimes relied on comparative evidence where the dose of the standard treatment was lower than current guidelines.

---

What Remains Uncertain in the Evidence Base

The evidence base highlights that results apply only to the populations studied and that evidence quality varies across studies. A significant area of uncertainty stems from trials using combination products, which means the individual effect of the core active ingredient (Natamycin or Nifuratel) may be difficult to confirm. Additionally, clinical research for Nifuratel often relies on meta-analyses where multiple infection types are grouped together, making specific findings for conditions like Bacterial Vaginosis uncertain. Finally, long-term effects are not fully established, and comparative evidence is lacking in certain subgroups.

Common questions about Экофуцин (FAQ)

Q: Is Экофуцин safe to take every day?

Экофуцин is typically prescribed for daily use, depending on the specific condition being treated. Following the precise instructions provided by a healthcare professional is key.

The official labeling generally advises against abrupt discontinuation, as this may be associated with adverse effects or the return of symptoms.

If a dose is missed, patients should refer to the instructions provided on the patient information leaflet or consult with their pharmacist or doctor for specific, personalized guidance. Dosing instructions cannot be provided here.

---

Q: Does Экофуцин interact with grapefruit juice or alcohol?

Drug monographs and product labels generally advise caution or avoidance regarding the use of both grapefruit juice and alcohol with Экофуцин.

• Grapefruit Juice: Grapefruit juice may interact with the metabolism of certain medications, which could potentially alter the concentration of Экофуцин in the body. It is important to discuss this interaction with a healthcare provider.
• Alcohol: Alcohol consumption can intensify common central nervous system side effects of Экофуцин, such as dizziness or sedation. Patients should discuss alcohol use and the potential for increased side effects with their healthcare provider.

---

Q: When is the best time of day to take Экофуцин?

The optimal timing for taking Экофуцин can depend on the specific formulation, the condition being treated, and the individual's response to the medication.

Since this medication may cause drowsiness, taking it later in the day or before bed may be advised by a healthcare provider to help manage this side effect. However, a doctor's recommendation is always necessary for personalized timing. Dosage initiation and titration are determined solely by the prescribing physician based on individual patient response and need.

---

Q: Can I stop taking Экофуцин once my symptoms improve?

Stopping Экофуцин should only be done under the direction of a healthcare professional.

Abruptly stopping certain medications can lead to potential adverse effects, including the re-emergence of original symptoms or the development of withdrawal reactions. The standard medical practice is to work with a doctor to develop a gradual schedule for reducing the dose over time, which is generally done to minimize potential side effects and maintain patient safety.

Official Storage and Disposal Requirements

Экофуцин vaginal suppositories must be stored under specific environmental controls as required by regulatory labeling to maintain product stability and potency.

Storage Condition	Requirement
Maximum Temperature	Store at a temperature not exceeding 25 C
Environmental Protection	Must be protected from light and stored in a dry place
Freezing Restriction	Do not freeze
Container	Keep in the original package

It is a mandatory safety instruction to keep the medicine out of the sight and reach of children.

Usage of the product is prohibited after the expiration date printed on the package. Unused or expired Экофуцин must be disposed of in accordance with local regulatory requirements, which often include medication take-back programs or specific household disposal methods.